Dose reduction or discontinuation may be necessary if you develop: Persistent, intolerable gastrointestinal symptoms despite supportive measures Acute pancreatitis (discontinue permanently) Severe hypoglycemia, particularly if taking concurrent insulin or sulfonylureas Acute kidney injury or worsening renal function Gallbladder disease symptoms (abdominal pain, jaundice) Diabetic retinopathy complications (particularly with semaglutide) Severe hypersensitivity reactions including anaphylaxis or angioedema Pregnancy or plans for pregnancy (for semaglutide, discontinue at least two months before planned conception
This is why we recommend baseline examination before starting therapy and ongoing monitoring throughout your treatment course, not just in the initial months
Sinal, C
doi: 10.1038/s41586-024-07419-8
Introduction GLP1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) suppress appetite by an average of 30 to 50 percent, but that number hides enormous individual variation
It may go without saying, but the old-fashioned way diet and exercise remains a preferred weight loss method
